Biomarkers.

Background: Alzheimer's disease (AD) continues to be the leading cause of dementia. Few treatment options exist to manage AD. It is essential to diagnose AD early to slow its progression; however, there are very limited diagnostic tools to accurately diagnose AD.

Biomarkers.

Background: In various neurological disorders, including Alzheimer's disease (AD) and AD-related dementia, there is a notable reduction in gamma-aminobutyric acid (GABA)ergic neurons, which represent the most abundant inhibitory neurons in the human brain. This study explores molecular association between miR-502-3p and the function of GABAergic neurons in AD.

Method: The investigation commenced by examining the status of GABA receptor proteins and miR-502-3p in postmortem AD brains.

Developing Topics.

Background: Recent studies have identified visual impairment as a potentially modifiable dementia risk factor. However, the underlying mechanism linking visual impairment and cognitive decline is still not fully understood. Additionally, there has been a dearth of research focusing on Latinos.

Drug Development.

Background: Reactive astrocytes and neuron death by excitotoxicity are observed in Alzheimer's disease (AD). DHA-H (2-hydroxy-docosahexaenoic acid; 2-OH-C22:6 n-3) is a molecule under development that has demonstrated therapeutic efficacy in both cellular and 5xFAD mouse model of AD. DHA-H is metabolized through α-oxidation to yield HPA (Heneicosapentaenoic acid; C21:5 n-3).